Sona Nanotech Reports 80% Response Rate in First-In-Human THT Cancer Therapy Study
-- Six out of ten patients experienced complete responses in treated tumors with an additional two patients demonstrating partial responses...
Melanoma
Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025
WOBURN, Mass., Oct. 19, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the...
Sona Nanotech To Host Investor Webinar To Discuss Clinical Study
Halifax, Nova Scotia--(Newsfile Corp. - October 17, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), announces...
Evaxion to present a breadth of data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025
Presentation will cover two-year clinical efficacy, immunogenicity and safety dataData will be presented at an oral session on October 17,...
Medicus Pharma Ltd. to Present at The Maxim Growth Summit 2025
EXECUTIVE CHAIRMAN & CEO OF MEDICUS TO PARTICIPATE IN A FIRESIDE CHAT WITH EQUITY RESEARCH ANALYST PHILADELPHIA, PENNSYLVANIA / ACCESS...
Castle Biosciences to Release Third Quarter 2025 Financial Results and Host Conference Call on Monday, Nov. 3, 2025
FRIENDSWOOD, Texas, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests...
Moderna Presents Promising Early Data for Its Investigational Cancer Antigen Therapy at the 2025 European Society for Medical Oncology Congress
mRNA-4359 has advanced into the Phase 2 portion of the ongoing Phase 1/2 trial CAMBRIDGE, MA / ACCESS Newswire /...
Medical Care Technologies (OTC PINK:MDCE) Advances AI Research to Help Identify Early Health Risks in Skin Cancer, Vision, Wound Care, and Mental Wellness
MESA, ARIZONA / ACCESS Newswire / October 9, 2025 / Medical Care Technologies Inc. (OTC Pink:MDCE), a developer of artificial...
Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer
VANCOUVER, British Columbia, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse...
Medical Care Technologies (OTC Pink:MDCE) Outlines Regulatory Roadmap: Dividing AI Health Platform Into Clinical and Consumer Divisions
MESA, ARIZONA / ACCESS Newswire / October 7, 2025 / Medical Care Technologies Inc. (OTC Pink:MDCE), an emerging innovator in...
Medical Care Technologies (OTC Pink:MDCE) Secures Access to One of the World’s Largest Public Skin Cancer Image Databases to Accelerate AI Development
MESA, ARIZONA / ACCESS Newswire / October 1, 2025 / Medical Care Technologies Inc. (OTC PINK:MDCE), an emerging developer of...
Children’s Hospital of Philadelphia Pediatric Cancer Researcher Receives Prestigious Grant for Advancing Rare Tumor Studies
Grant supports CHOP's dedication to understanding and treating rare tumors PHILADELPHIA, Sept. 29, 2025 /PRNewswire/ -- Children's Hospital of Philadelphia...
ELEPHAS BIOSCIENCES WELCOMES DR. JEROME GALON TO THE COMPANY’S EXPANDING SCIENTIFIC ADVISORY BOARD
Internationally recognized expert joins to support the organization's commercialization strategy MADISON, Wis., Sept. 25, 2025 /PRNewswire/ -- Elephas Biosciences Corporation...
AIM ImmunoTech Secures Patent in Japan Through 2039 for Novel Cancer Therapy Combining Ampligen® (Rintatolimod) with Checkpoint Inhibitors
Patent supports AIM’s strategy to expand international market protection, providing opportunities for licensing, collaborations, and long-term revenue growth Japan is...
Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
HOUSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”),...
Medicus Pharma Ltd. To Present at Brookline Capital Markets
The Company will provide an update on its novel Doxorubicin containing Microneedle Array (D-MNA) treatment to non-invasively treat basal cell...
Mural Oncology Announces Commencement of Mailing of Definitive Proxy Statement and Details of Scheme Meeting and Extraordinary General Meeting
WALTHAM, Mass. and DUBLIN, Ireland, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc, (Nasdaq: MURA) (“Mural”), a clinical-stage immuno-oncology...
IO Biotech Announces Late-Breaking Abstract in Advanced Melanoma Selected for Oral Presentation at ESMO Congress 2025
Oral presentation will highlight the results from the randomized Phase 3 trial (IOB-013/KN-D18) of IO102-IO103 cancer vaccine plus pembrolizumab for...
Castle Biosciences Honored with a Greater Pittsburgh Top Workplaces 2025 Award
FRIENDSWOOD, Texas, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that...
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
Registration Link Below for September 30, 2025 12 PM EST Presentation and Live Q&AKing of Prussia, Pennsylvania--(Newsfile Corp. - September...